Treatment of Advanced Prostate Carcinoma in Kyrgyzstan

Kubat Iyazaliev; Michael Siegsmund; Hans Leweling

Nephro-Urology Monthly

Current Issue All Issues In Press Accepted Manuscripts Search

Journal Information Boards and Committees Indexing and Listing Sources Journal Metrics Open Peer Review (OPR)Publication Ethics and Malpractice Statement Contact Us Support Reviewer and AE Registration Form

APC

Authors Guide Submit Manuscript

Treatment of Advanced Prostate Carcinoma in Kyrgyzstan

Author(s):

Kubat Iyazaliev^1,*,

Michael Siegsmund²,

Hans Leweling³

1National Cancer Research Center, Department of Urology, Tynystanov, Street 64-27, kubat.iyazaliev@gmail.com, Kyrgyzstan

2Department of Urology, University of Heliosweg, Germany

33Department of Internal Medicine, University of Heidelberg, Germany

Nephro-Urology Monthly:Vol. 2, issue 1; 255-264

Article type:Research Article

Received:May 04, 2009

Accepted:Jul 15, 2009

How to Cite:Kubat IyazalievMichael SiegsmundHans LewelingTreatment of Advanced Prostate Carcinoma in Kyrgyzstan.Nephro-Urol Mon.2(1):255-264.

Abstract

Background and Aims: We compared two treatment methods on patients with advanced prostatic carcinoma in two treatments groups: primary metastatic prostatic carcinoma and metastasized recurrent tumor after primary treatment.

Methods: A retrospective review was performed on a total 302 patients with distant metastases between 1986 and 1995: 146 patients with systemically recurrent prostate cancer (group 1) and 156 patients with primary metastasized carcinoma (group 2). In each group the patients were treated by chemo-hormonal therapy or only by hormonal therapy. In Group 1 patients were treated with hormone deprivation alone by fosfestrol (n=68) and a combination of polychemotherapy and fosfestrol (n=78). In Group 2 only hormonal treatment had 62 (39.7 %) and a combined chemo-hormonal therapy had 94 (60.3%) patients. The patients were also grouped by the load of metastases, in low (< 5 metastases), intermediate (> 5 metastases confined to one organ or skelet) and high (multiorgan metastasis).

Results: A statistically significant prolonged survival was found in Group 1 patients treated with chemo-hormonal therapy compared to the patients treated with hormonal therapy alone. The median survival in the chemo-hormonal group was 24.5 months compared to 8 months in hormone group (p < 0.0001). The amount of metastases did not change the significant disease specific survival advantage of the combined chemo-hormonal treatment. The same significant survival advantage was demonstrated in Group 2 for the combination treatment compared to estrogen treatment alone. The median overall survival in the chemo-hormonal group was 25 months, compared to the 10.5 months for the patients treated with hormone ablation alone (p < 0.0001). This difference was also maintained after stratification for tumor grade or metastasis load.

Conclusions: Chemo-hormonal therapy significantly prolonged overall and disease specific survival over hormonal therapy alone in recurrent metastasized and primary metastasized cancers. Combined chemo-hormonal treatment should be started early in metastasized cancer, before the outgrow of hormone refractory tumor cell clones.

Keywords

Full Text

Full text is available in PDF

comments